文献支持WHI-P97 是一种有效的选择性 JAK-3 抑制剂。WHI-P97 在动物模型中有效预防过敏性哮喘的发展。

价格： ￥900

品牌：medchemexpress(MCE)

货号：HY-11067

产品详情

WHI-P97

WHI-P97 是一种有效的选择性 JAK-3 抑制剂。WHI-P97 在动物模型中有效预防过敏性哮喘的发展。

美国medchemexpress（MCE)浙江省一级代理:杭州昊鑫生物科技股份有限公司
MCE中国是全球领先的科研化学品和生物活性化合物供应商，总部位于美国新泽西。我们的产品范围覆盖各种抑制剂、激动剂、API和化合物库。专业、高效的企业灵魂铸造了在行业的卓越地位。热情和充满活力的研发团队拥有着大量的化学和生物科学家。专注于生物活性化合物，拥有着多年的发展历程和丰富的行业经验。从产品的HNMR数据解析到生物活性数据，从客户的询价到产品的售后服务，我们拥有着完善的管理体系，从而保证我们的服务更加高效、准确。努力为中国的医药行业发展注入新的活力，我们将成为您研发工作值得信赖的伙伴。

生物活性
WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo[1].

IC50 & Target[1]
JAK3
11 μM (IC50)

体外研究
WHI-P97 inhibits the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcεRI crosslinking by >90% at low micromolar concentrations[1].
WHI-P97 (30 μM) stantially reduces the IgE/antigen-induced LTC4 release from mast cells[1].

体内研究
WHI-P97 is very well tolerated in mice, with no signs of toxicity at dose levels ranging from 5 μg/kg to 50 mg/kg, and LD10 is not reached at a 50 mg/kg dose level when administered as a single i.p. or i.v. bolus dose[1].
WHI-P97 (i.v. injection; 40 mg/kg; single dose) has an elimination half-life (t1/2) of 58.9 min and systemic clearance (CL) of 891 ml/h/kg in CD-1 mice and a t1/2 of 84.2 min and CL of 1513 ml/h/kg in BALB/c mice. The values for AUC and Cmax are 107.3 μM and 296.7 μM, respectively, in CD-1 mice. And the IC50 values are 58.4 μM and 212.7 μM, respectively, in BALB/c mice. The large volume of distribution are 322 ml/kg in CD-1 mice and 415 ml/kg in BALB/c mice[1].
WHI-P97 (intraperitoneal injection; 40 mg/kg; 24 days) prevents ovalbumin-sensitized mice the development of airway hyper-responsiveness to methacholine in a dose-dependent fashion in mice. WHI-P97 inhibits the eosinophil recruitment to the airway lumen after the ovalbumin challenge in a dose-dependent fashion[1].

Animal Model:   BALB/c mouse model of allergic asthma[1]
Dosage:   40 mg/kg
Administration:   intraperitoneal injection; 24 days
Result:   Showed promising biological activity in a mouse model of allergic asthma at nontoxic dose levels.

分子量
455.10

性状
Solid

Formula
C16H13Br2N3O3

CAS 号
211555-05-4

运输条件
Room temperature in continental US; may vary elsewhere.

储存方式
Powder   -20°C   3 years
4°C   2 years
In solvent   -80°C   6 months
-20°C   1 month
溶解性数据
In Vitro:
DMSO : 3.33 mg/mL (7.32 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度溶剂体积质量   1 mg   5 mg   10 mg
1 mM   2.1973 mL   10.9866 mL   21.9732 mL
5 mM   0.4395 mL   2.1973 mL   4.3946 mL
10 mM   ---   ---   ---
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 0.59 mg/mL (1.30 mM); Clear solution

2.
请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 0.59 mg/mL (1.30 mM); Clear solution

参考文献	[1]. R Malaviya, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther. 2000 Dec;295(3):912-26. [Content Brief]